Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and the year ended December 31, 2018 financial results at 7:00 am Eastern Time on Thursday, March 28, 2019. Tricida will host a conference call and webcast at 8:00 am Eastern Time to discuss its financial results and business progress. The call or webcast may be accessed as follows:
|Tricida Fourth Quarter and Full-Year 2018|
|Thursday, March 28, 2018|
|8:00 am Eastern Time|
A replay of the webcast will be available on Tricidas website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.
Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its drug candidate, TRC101, a non-absorbed, orally-administered polymer designed as a potential treatment for metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately three million patients with CKD in the United States. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101 in patients with CKD and metabolic acidosis. Tricida plans to submit a New Drug Application (NDA), in the second half of 2019, seeking approval of TRC101 through the U.S. Food and Drug Administrations (FDAs) Accelerated Approval Program.
For more information about Tricida, please visit www.Tricida.com.
Cautionary Note on Forward-Looking Statements
This press release includes forward-looking statements, including for example, statements about our ability to submit an NDA for TRC101 under the FDAs Accelerated Approval Program. Forwardlooking statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forwardlooking statements. These risks and uncertainties include, among others, the timing of Tricidas NDA submission; that many drug candidates that have completed Phase 3 trials do not become approved drugs on a timely or cost effective basis or at all; there can be no assurance that the FDA would approve an NDA under the Accelerated Approval Program, or at all, and even if approval for a drug is obtained, there can be no assurance that it will be adopted in the market or accepted as a benefit to patients and healthcare providers; possible safety and efficacy concerns and that we completely rely on third-party suppliers to manufacture TRC101. The forward-looking statements contained in this press release reflect Tricidas current views with respect to future events, and Tricida does not undertake and specifically disclaims any obligation to update any forward-looking statements.
Jackie Cossmon, IRC
Vice President of Investor
Relations and Communications